Targeting Midbodies in Ovarian Cancer Stem Cells as a Therapeutic Strategy
Abstract
The etiology and early events in the development and progression of ovarian tumorigenesis are among the least understood of all human malignancies. A major difficulty in the treatment of ovarian cancer is tumor recurrence and chemoresistance. One explanation for these impediments to a cure for ovarian cancer is that a subset of cancer cells, called cancer stem cells (CSCs) or cancer initiating cells (CICs) , is both the source of ovarian cancer and the major contributor to the refractory nature of ovarian cancer to chemotherapeutic challenge [4-7]. For these reasons, a better understanding of ovarian cancer stem cells and their contribution to ovarian cancer is essential and may provide the best strategy to ameliorate this disease. In the last decade, the cancer stem cell theory has been supported by many studies and has become an attractive hypothesis for the generation and propagation of human cancers. Putative ovarian CSCs have been identified in mouse and human and used to successfully induce tumor formation and serial tumor propagation in mice. However, there has been limited success in therapeutic targeting of CSCs for ovarian tumor eradication.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2013
- Accession Number
- ADA602881
Entities
People
- Stephen Doxsey
Organizations
- University of Massachusetts Medical School